Omnicell, Inc. (NASDAQ:OMCL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Omnicell, Inc. (NASDAQ:OMCL) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $44.83.

Several equities research analysts recently issued reports on OMCL shares. JPMorgan Chase & Co. decreased their target price on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $37.00 price target (up from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. Benchmark reduced their price target on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Wall Street Zen raised shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Tuesday, May 20th. Finally, Bank of America lifted their price target on shares of Omnicell from $30.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday, May 23rd.

Omnicell Price Performance

Omnicell stock opened at $29.61 on Wednesday. Omnicell has a 12-month low of $22.66 and a 12-month high of $55.75. The stock has a market capitalization of $1.39 billion, a P/E ratio of 109.67, a P/E/G ratio of 7.53 and a beta of 0.78. The firm’s 50-day moving average is $30.70 and its two-hundred day moving average is $38.41. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.10. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The company had revenue of $269.67 million for the quarter, compared to analysts’ expectations of $260.18 million. During the same period last year, the company earned $0.03 EPS. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. Equities analysts predict that Omnicell will post 1.09 earnings per share for the current year.

Institutional Trading of Omnicell

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Shaker Investments LLC OH bought a new stake in shares of Omnicell in the fourth quarter worth $550,000. Empowered Funds LLC bought a new stake in Omnicell during the fourth quarter valued at $388,000. Jane Street Group LLC increased its stake in Omnicell by 7.4% during the fourth quarter. Jane Street Group LLC now owns 54,282 shares of the company’s stock valued at $2,417,000 after purchasing an additional 3,725 shares during the last quarter. CIBC Asset Management Inc bought a new stake in Omnicell during the fourth quarter valued at $201,000. Finally, Invesco Ltd. increased its stake in Omnicell by 2.4% during the fourth quarter. Invesco Ltd. now owns 219,453 shares of the company’s stock valued at $9,770,000 after purchasing an additional 5,063 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.